Large CRE Deals Come Roaring Back: What Q3 2025 Means for Today’s Professionals

City skyline sunrise

After several quarters of hesitation, the U.S. commercial real estate market saw a major pulse of confidence in Q3 2025. According to fresh data from Altus Group, large single‑asset deals valued at $10 million or more surged back into the spotlight, hitting $76 billion for the quarter — the strongest performance since 2022.

For professionals across real estate, finance, and investment sectors, this shift isn’t just a statistic. It’s a directional signal: liquidity is returning, high‑value buyers are stepping back in, and the upper tier of the market is showing long‑awaited signs of normalization.

The Return of the Big Deal

Altus Group’s Q3 2025 Investment & Transactions Report reveals a notable trend reversal. For the first time in several quarters, both quarterly and annual deal counts increased. But what truly stands out is the composition — large, single‑asset transactions made a powerful comeback.

Q3 2025 recorded 1,826 single‑asset deals above $10M — the highest since Q3 2022.

This accounted for nearly 68% of all single‑asset dollars traded, a level not seen since mid‑2022. Even outside the record‑breaking volatility of the post‑pandemic period, this quarter delivered the strongest growth rate for major deals in more than a decade.

A Market Rebound — But Not a Full Return to Peak Conditions

Despite the strong resurgence in activity, overall transaction volume still trails the highs of 2021 and 2022. The main cause? Deal size. The median large‑deal value landed at $19.6 million, roughly 9% below the late 2021 peak of $21.4 million.

Every major sector remains below its historic high:

Industrial: 1.7% below peak
Multifamily: 8.2% below peak
Office: 23.8% below peak
Retail: 6.1% below peak

Office continues to be the long‑term laggard, while industrial remains closest to full recovery. Multifamily, meanwhile, is showing renewed momentum with a 14.2% rise from post‑pandemic lows.

Pricing Trends Hint at Stabilization

The median price per square foot across property types rose 0.6% both quarterly and annually — a subtle but encouraging sign of stabilization. Office properties, however, continue their downward drift, losing 3% QoQ and 4.4% YoY.

Investors appear increasingly comfortable re‑entering the market, even if valuations remain below peak highs — suggesting improved price discovery and growing confidence in long‑term underwriting.

Why This Matters for Today’s Professionals

Commercial real estate often acts as a barometer for broader economic risk appetite. The return of large‑scale deals signals that institutional players believe conditions are returning to equilibrium. For real estate agents, mortgage professionals, and investors, this means new opportunities are emerging.

For those looking to upskill or transition into CRE roles, now is the time to enhance your professional profile. Schools like Cameron Academy provide flexible, career‑focused licensing and continuing education designed to keep professionals competitive during shifting market cycles.

A Step Toward Market Normalization

The key question now: will this momentum continue? As borrowing costs settle and underwriting clarity improves, Q4 and early 2026 could bring even greater liquidity — or a cautious pause.

For now, Q3 stands as the clearest sign in years that capital is flowing back into the big‑deal segment — and that investors are once again ready to make meaningful, future‑focused moves.

Read the full Altus Group analysis

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

Precision Medicine Market: A Tailored Approach Revolutionizing Healthcare

With increasing governmental and private investments, the demand for precision medicine is expected to rise steadily. The commitment to addressing chronic conditions, coupled with strategic industry collaborations and advanced diagnostic tools, will sustain market growth.

U.S. Wearable Medical Devices Market: Growth Trends and Future Prospects

The U.S. wearable medical devices market, currently valued at an estimated $11.45 billion in 2023, is set to experience an astronomical rise to approximately $112.67 billion by 2033.

By |December 3, 2024|Categories: Article, Healthcare, Technology|Tags: |0 Comments

The Future of Real Estate Market: What Lies Ahead?

The real estate market is on the brink of transformation, captivating the attention of buyers, sellers, investors, and industry professionals. As we look toward the end of 2024, experts predict a shift in the landscape, particularly with home prices expected to decline due to increased inventory levels.

By |December 3, 2024|Categories: Article, Market Trends, Real Estate|Tags: , |0 Comments

Bridging the Healthcare Gap in Rural Areas with Telehealth

According to the World Health Organization (WHO), nearly two billion people in rural and remote areas worldwide lack access to essential healthcare solutions. This staggering statistic highlights a critical issue: the digital divide that limits telehealth services, primarily due to inadequate broadband access.

By |December 2, 2024|Categories: Article, Healthcare, Technology|Tags: , |0 Comments

Navigating Ethical Challenges: AI in Healthcare

As AI becomes a staple in medical practice, it carries the risk of reinforcing existing biases entrenched in historical data. These biases can lead to skewed outcomes, particularly affecting marginalized communities such as the LGBTQIA+ and certain ethnic groups.

By |December 2, 2024|Categories: Article, Ethics, Healthcare|Tags: , |0 Comments

New SCLC Biomarkers Enable Advances in Precision Medicine Approaches

A groundbreaking study published in Volume 15 of Oncotarget on October 11, 2024, titled 'Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC' showcases pivotal advancements in the fight against small cell lung cancer (SCLC).

By |December 2, 2024|Categories: Article, Cancer Treatment, Medical Research|Tags: , |0 Comments